Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of major importance, occupational exposure to Cr(VI) compounds has been firmly associated with the development of lung cancer.
|
31623305 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to (i) identify biological pathways that are consistently modulated by Cr(VI) in the lung through the compilation of transcriptomic-based databases, (ii) predict interactions between epigenetic regulators and transcriptional responses, and (iii) relate findings to previous literature to postulate a mechanism of action underlying Cr(VI)-induced lung cancer involving changes in genomic/epigenomic signatures.
|
30690063 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexavalent chromium [Cr(VI)] is known to cause lung cancer in workers of certain industries, but an association with stomach cancer is uncertain and widely debated.
|
30896278 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, the explicit epigenetic alterations induced by Cr(VI) in lung cancer including histone modifications and miRNAs, remain understudied.
|
31228494 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexavalent chromium [Cr(VI)] is one of the most common environmental carcinogen causing lung cancer in humans; however, the mechanism of Cr(VI) carcinogenesis remains elusive.
|
31504995 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexavalent chromium [Cr(VI)] is a common human carcinogen associated with lung cancer and other pulmonary diseases as exposure to excessive Cr(VI) induces malignant transformation in human lung epithelial cells.
|
29782351 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexavalent chromium [Cr(VI)] is an important human carcinogen associated with pulmonary diseases and lung cancer.
|
28881718 |
2017 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Paired box 5 is a frequently methylated lung cancer tumour suppressor gene interfering β-catenin signalling and GADD45G expression.
|
26843424 |
2016 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hexavalent chromium [Cr(VI)] is a well-known human carcinogen associated with an increased risk of lung cancer.
|
27323401 |
2016 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a MOA analysis for Cr(VI)-induced lung cancer evaluating toxicokinetic and toxicological data in humans and rodents and mechanistic data to assess plausibility, dose-response, and temporal concordance for potential MOAs.
|
25174529 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexavalent chromium [Cr(VI)] is a well-known human carcinogen associated with the incidence of lung cancer.
|
25448439 |
2014 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexavalent chromium [Cr(VI)] is an important human carcinogen associated with pulmonary diseases and lung cancer.
|
23518002 |
2013 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hexavalent chromium [Cr(VI)] is a well-known human carcinogen associated with the incidence of lung cancer.
|
21742780 |
2011 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cr(VI) exposure-related lung cancer has a high mutation incidence in the p53 gene.
|
16251206 |
2006 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since humans are frequently exposed to both Cr(VI) and PAHs, it is possible that Cr(VI) and PAHs have a synergistic effect on mutagenecity and cytotoxicity that contributes to the high incidence of lung cancer associated with exposure to both agents.
|
15518579 |
2004 |